Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$15.91 USD
-0.51 (-3.11%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.95 +0.04 (0.25%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SRPT 15.91 -0.51(-3.11%)
Will SRPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Other News for SRPT
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
Buy/Sell: Wall Street's top 10 stock calls this week
SRPT September 12th Options Begin Trading
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results | SRPT Stock News